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Purpose: Several reactions leading to numerous eﬀects are regulated by IL-22.
However, the relationship between IL-22 and immunopathogensis of allergic rhinitis (AR) has been rarely investigated. The aim of the present study was to
investigate the levels of IL-22 and IL-17A in AR patients and their association with clinical severity of persistent allergic rhinitis (PAR).
Materials and methods: Thirty mild persistent allergic rhinitis (M PAR) patients, thirty moderate/severe persistent allergic rhinitis (M/S PAR) patients, and thirty
healthy controls were enrolled in this study. Local production of IL-22 and IL-17A in PAR patients and healthy controls' nasal mucosa was examined by im-
munohistochemistry (IHC) and real-time polymerase chain reaction (RT-PCR) techniques. Serum levels of IL-22, IL-17A, speciﬁc immunoglobulin E (sIgE), and total
IgE (tIgE) in PAR patients and healthy controls were determined by ELISA. In addition, blood eosinophil, nasal eosinophils per ﬁeld, and total nasal syndrome score
(TNSS) were also assessed.
Results: In comparison with healthy controls, production of IL-22 and IL-17A in M/S PAR patients increased signiﬁcantly. Furthermore, serum levels as well as the
mean number of IL-22+ and IL-17A+ cells in nasal mucosa correlated with sIgE, nasal eosinophil count, and TNSS.
Conclusion: The results of the present study provide the ﬁrst evidence that local production of IL-22 might be expressed in PAR patients. The expression of IL-22 and
IL-17A, and their correlations with clinical parameters in PAR patients suggest the role of these cytokines in the events involved in the development of PAR.
1. Introduction
Allergic rhinitis (AR) is a non-infectious disease caused by the
contact of allergens during the presence of IgE in the nasal mucosa. A
recently conducted study revealed that imbalance of Th17 and Treg
cells and allergic rhinitis are highly correlated [1]. Furthermore, an-
other recent study in this regard indicated that Th17 cells, which are
classiﬁed as a subclass of TCD4+ cells, play a prominent role in the
pathogenesis of allergic diseases and represent a new mechanism in the
development of allergic rhinitis [2].
Th17 cells are recognized to produce a variety of cytokines such as
IL-6, IL-17, TNFα, and IL-22. IL-17A is an inﬂammatory cytokine, which
can aﬀect a wide range of respiratory cells and can also induce the gene
expression of cytokines and mucosal proteins [3,4].
Numerous experiments have addressed the role of IL-17A in pa-
thogenesis of AR [5–7]. The results of studies targeting children
suﬀering from AR revealed that there was a signiﬁcant positive corre-
lation between IL-17A mRNA expression, which was caused by the
presence of allergens inside the peripheral blood mononuclear cells
(PBMC), and symptom medication score [5,8]. In addition, the levels of
IL-17A in nasal lavage of patients with AR were signiﬁcantly higher
than those of healthy individuals in the control group [8]. Moreover,
experiments using mouse models indicate that IL-17A is involved in
both the development and regulation of AR [7,9,10].
Moreover, IL-22 can be regarded as an important factor in mod-
ulation of tissue response during the inﬂammation and carry out a
prime function in inﬂammatory diseases [11]. IL-22 belongs to the fa-
mily of IL-10 cytokines, and one of its most signiﬁcant sources is TH17.
IL-22 receptor is expressed over the surface of epithelial cells of re-
spiratory system and can induce the expression of special antimicrobial
peptides and proteins, which can cause cell dediﬀerentiation and sur-
vival [12–15]. Furthermore, an array of experiments proved that
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neutralization of IL-22 can increase the allergic response and migration
of eosinophils into the lungs [16]. IL-22 regulates diﬀerent processes
and causes diﬀerent eﬀects. As the above-presented review of literature
indicates, only few studies have been conducted on the local expression
of IL-17A and IL-22 in patients with AR. Hence, the present study aimed
at comparing the expressions of IL-17A and IL-22 in inferior turbinate
mucosa of patients with mild and moderate/severe AR and those of
healthy individuals. Therefore, the present study was undertaken to:
1) Compare the human serum expression levels of IL-17A and IL-22 in
M/S AR patients, M AR patients, and healthy controls.
2) Evaluate the expression of IL-17A and IL-22 in human inferior tur-
binate mucosa and compare the expression levels in M/S AR pa-
tients, M AR patients, and healthy controls.
3) Specify any correlations between IL-17A and IL-22 expressions with
various pathological parameters.
2. Material and methods
2.1. Participants
This study was conducted in the otolaryngology clinic of Kashani
Hospital aﬃliated with Shahrekord University of Medical Sciences,
Shahrekord, Iran. The present study was approved by the Ethics
Committee of Shahrekord University of Medical Sciences (ETHICS
COMMITTEE CERTIFICATE OF APPROVAL Numbered 92-7-23).
Moreover, written informed consents were obtained from all partici-
pants. Sixty patients with previously demonstrated and not treated al-
lergic Rhinitis, who had not received any drugs within the past four
weeks, were chosen to participate in the study. Diagnosis of AR was
based on the ARIA guideline (Allergic Rhinitis and its Impact on
Asthma, 2008 update) [17]. The exclusion criteria were the presence of
any inﬂammatory and autoimmune diseases and history of recurrent
infections, chronic sinusitis and smoking. Patients who had previously
used anti-allergy drugs, inhaled corticosteroids, or used systemic ster-
oids within the past four weeks as well as those who were active
smokers were excluded from the study. According to the results of prick
test and presence or absence of clinical symptoms including sneezing,
rhinorrhea, and nasal congestion over most days, the selected patients
were divided into two groups consisting of mild persistent allergic
rhinitis (M PAR) (n= 30) and moderate/severe allergic rhinitis (M/S
PAR) (n=30). Duration of the disease did not signiﬁcantly diﬀer be-
tween the groups of patients with M PAR and M/S PAR (Table 2).
Moreover, thirty healthy, unrelated and age and gender matched con-
trol participants with no personal or family history of asthma, allergic
rhinitis, and other inﬂammatory disease who had normal nasal mucosa
and were admitted for augmentation rhinoplasty.
2.2. Prick test
Skin prick testing (SPT) was performed according to the guidelines
of European Academy of Allergy and Clinical Immunology [18] and
with consideration of the positive results (mean wheal diameter >
3mm) speciﬁed for common aeroallergens.
2.3. Blood sampling and cytokine measurements by ELISA
Blood samples of patients suﬀering from house dust mite (Astra
biotec, Germany) were obtained for assessment of eosinophil counts,
serum tIgE (Pishtazteb, Iran), and sIgE using ELISA technique. Blood
collection, handling, and storage were performed by the same re-
searchers. Serum levels of IL-17A and IL-22 were determined by ELISA
assays according to the manufacturer's instructions (Abnova, Taiwan).
All assays were carried out in duplicate.
2.4. Hematoxylin and Eosin (H&E) staining and immunohistochemistry
During surgery in the otolaryngology clinic of Kashani Hospital, the
inferior turbinate mucosa was obtained by a surgeon from the all pa-
tients and healthy individuals. Biopsy specimens were submerged im-
mediately in 10% buﬀered formalin and prepared for paraﬃn embed-
ding. Then, the paraﬃn blocks were cut into sections of four microns
thick, which mounted on glass slides. They were prepared for routine H
&E stain to perform the conventional histopathology and for im-
munohistochemistry to examine the presence of eosinophil in nasal
mucosa in all groups. To perform the immunohistochemical examina-
tion of IL-17A and IL-22 proteins, the labeled streptavidin-biotin com-
plex method and mouse and rabbit speciﬁc HRP plus (ABC) (Abcam,
England) were used. From each participant, two sections were dried in
a 70 °C oven overnight, deparaﬃnized using xylene, and then re-hy-
drated using a series of alcohols (100%, 100%, 80%, and 70%). The
sections were then microwaved for 3min with maximum temperature
and then for 25min with minimum temperature in citrate phosphate
buﬀer (pH 6.0) for antigen retrieval. Blocking of the endogenous per-
oxidase activity was performed using 0.3% H2O2 in TBS for 15min. The
sections were then incubated with protein block (Abcam, England) for
10min to block the non-speciﬁc background staining. Polyclonal anti-
IL-17A and anti-IL-22 was generated by immunizing the rabbits
(Abcam-England). 1 mg/ml of these antibodies used against IL-17A and
IL-22 were applied as the respective primary antibodies, and tissue
sections were incubated overnight at 4 °C. Afterward, the sections were
washed with 1% bovine serum albumin (BSA) in Tris buﬀer solution
(TBS). Then, biotinylated goat anti-rabbit and mouse IgG was applied,
and the sections were incubated for 1 h at room temperature. Slides
were developed with diaminobenzidine and counterstained with he-
matoxylin. Positive stain cells were calculated in ﬁve ﬁelds at the power
of (10×10), where the highest cellular inﬁltration was noticed. The
mean number of cells was then evaluated.
2.5. Quantitative PCR analysis
Total RNA was extracted from biopsies of the nasal inferior turbi-
nate using Biozol reagent (Bioﬂux, Japan) according to the manufac-
turer's instructions. The quantity and quality of the RNA were measured
by spectrophotometry at the wavelength absorption ratio of 260/
280 nm. Some RNA samples (1 mg/ml) were coupled with DNase I
(Thermo Scientiﬁc, Lithuania) for 30min to avoid DNA contamination.
Complementary DNA was synthesized using 1mg of total RNA in a
20ml reaction tube (Thermo Scientiﬁc, Lithuania) following the in-
structions provided by the manufacturer. PCR ampliﬁcation reactions
were conducted using a SYBR Green master mix (Takara, Japan). The
reactions were incubated at 25 °C for 5min, at 42 °C for 1 h, and at 72 °C
for another 5min. The primer sequences used for each gene, which was
included in the study, are listed in Table 1. β-Actin was used as the
internal control. All measurements were performed in duplicate. The
levels of IL-17A and IL-22 mRNA expressions were assessed in relation
to the housekeeping gene β-actin expression. Standard curves were
prepared, and the eﬃciency was determined for each set of primers.
The speciﬁed eﬃciency was typically above 90%. The data were ex-
pressed as a fold-change using comparative cycle threshold method
Table 1
Sequences of PCR primers.
Primer Sequence
beta-Actin Forward primer: 5-AGCCTCGCCTTTGCCGA-3
Reverse primer: 5-CTGGTGCCTGGGGCG-3
IL-17A Forward primer: 5-AATCTCCACCGCAATGAGGA-3
Reverse primer: 5-ACGTTCCCATCAGCGTTGA-3
IL-22 Forward primer: 5-GCAGGCTTGACAAGTCCAACT-3
Reverse primer: 5-GCCTCCTTAGCCAGCATGAA-3
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(ΔΔct method). The relative gene expression was determined by the 2^-
ΔΔct method (Table 1).
2.6. Assessment of IL-17A and IL-22 levels by ELISA
IL-17A and IL-22 levels in the normal, M PAR, and M/S PAR serums
were measured using ELISA with the consideration of the manufac-
turer's protocol (Abnova, Taiwan). The data were expressed as pg/mg
protein concentration. Protein concentration was determined using the
ELISA Reader (Stat fax 2100, USA).
2.7. Statistical analysis
Statistical analyses were carried out using SPSS for windows (ver-
sion 11, IBM SPSS statistics). In this study, Chi-square test was made use
of to compare the diﬀerences of gender, congestion, rhinorrhea, and
sneezing between the healthy controls and patients with M PAR and M/
S PAR. A one-way ANOVA along with post-hoc Tukey test was per-
formed to evaluate whether the values obtained by real-time PCR, IHC,
and ELISA diﬀer among the nasal mucosa of healthy controls and pa-
tients with M PAR and M/S PAR. Moreover, student's t-test was used to
analyze the diﬀerences of sIgE between M PAR and M/S PAR patients.
Correlations were assessed using the Pearson's correlation coeﬃcient
test. A value of P < 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Clinical characteristics of the participants
The characteristics of patients with allergic rhinitis and healthy
controls are presented in Table 2. Age was similarly distributed among
the healthy controls and the patients with allergic rhinitis. Duration of
disease did not signiﬁcantly diﬀer between two groups of M PAR and
M/S PAR patients (Table 2). In comparison with healthy individuals,
serum tIgE levels were higher in patients with M PAR and M/S PAR
(Table 3).
3.2. Gene expression levels of IL-17A and IL-22 in nasal mucosa
The gene expression levels of IL-17A and IL-22 were determined in
healthy, M PAR, and M/S PAR nasal mucosa using real-time PCR. In
comparison with healthy nasal mucosa, signiﬁcantly increasing ex-
pression levels of IL-17A and IL-22 were observed in nasal mucosa of
patients with M PAR and M/S PAR (Fig. 1A, B) (Table 3).
3.3. Local protein expression levels of IL-17A and IL-22 in nasal mucosa
The number of IL-17A+ and IL-22+ cells in nasal mucosa was sig-
niﬁcantly higher in M/S PAR group compared with that of the control
group (P < 0.05; Fig. 2A, B). However, the diﬀerence between the
number of IL-17A+ cells in control group and M PAR group was not
signiﬁcant (P < 0.05). The diﬀerence between numbers of IL-22+ cells
in M PAR and M/S PAR group was statistically signiﬁcant (P < 0.05)
(Table 3). Immunohistochemical localization of IL-17A+ and IL-22+
cells in nasal mucosa of healthy controls and patients with allergic was
shown in Fig. 3.
3.4. Pathophysiological signiﬁcance of IL-17A expression in nasal mucosa
of patients with M/S PAR
A signiﬁcant and positive correlation was observed between the
number of IL-17A+ cells in the nasal mucosa and the total nasal
symptom score (TNSS), which was determined considering the sum of
sneezing, rhinorrhea, and congestion scores (R= 0.680; P < 0.05;
data not shown). In details, the scores of congestion (R=0.476;
P < 0.05), rhinorrhea (R=0.377; P < 0.05), and sneezing
(R=0.508; P < 0.05) positively correlated with the number of IL-
17A+ cells. The degree of eosinophil inﬁltration into the nasal mucosa
was highly and positively correlated with the number of IL-17A+ cells
(R=0.564; P < 0.05; data not shown). Moreover, there were sig-
niﬁcant correlations between IL-17A+ cells and sIgE (R=0.501;
P < 0.05; data not shown), serum IL-17A (R=443; P < 0.05; data
not shown), number of IL-22+ cells (R=0.508; P < 0.05; data not
shown), and tIgE (R= 0.388; P < 0.05; data not shown). However, the
number of IL-17A+ cells did not statistically correlate with the blood
eosinophil counts (R=0.311; P > 0.05; data not shown).
3.5. Pathophysiological signiﬁcance of IL-22 expression in nasal mucosa of
patients with M/S PAR
There was a signiﬁcant correlation between IL-22+ cells and TNSS
(R=0.588; P < 0.05; data not shown). In details, the associations
between IL-22+cells and congestion were noticeable (R=0.518;
P < 0.05); however, there were not any correlations between local
production of IL-22 and rhinorrhea (R= 0.33; P > 0.05) and sneezing
(R=0.305; P > 0.05). Furthermore, the correlations between IL-22+
cells and the degree of eosinophil inﬁltration into the nasal mucosa
(R=0.405; P < 0.05; data not shown), sIgE (R= 0.517; P < 0.05;
data not shown), serum IL-22 (R=0.776; P < 0.05; data not shown),
tIgE (R=0.37; P < 0.05; data not shown), and blood eosinophil
counts (R=0.427; P < 0.05; data not shown) were statistically sig-
niﬁcant.
Table 2
Subject characteristics.
Variable Healthy controls M PAR patients M/S PAR patients
Gender (male/female) 18/12 20/10 22/8
Age 28.5 ± 6.42 26.03 ± 4.03 26.7 ± 4.87
SIgE for house dust
mite (IU/mL)
0 0.51 ± 0.15 4.57 ± 5.56
TIgE (IU/mL) 82.63 ± 43.88 236.3 ± 33.24 1061.1 ± 88.41
Blood eosinophil counts 74.5 ± 40.02 255.7 ± 70.96 607.27 ± 117.37
Degree of eosinophil
inﬁltration into
nasal mucosa
0.5 ± 0.5 1.7 ± 0.59 3.63 ± 1.88
Disease duration 0 15.63 ± 2.09 17.17 ± 4.39
Table 3
Comparison between the baseline characteristics, IL-17A gene expression, IL-22
gene expression, serum levels of IL-17A and IL-22, and IL-17A+ and IL-22
positive cells per ﬁeld among healthy control, patients with M PAR, and pa-
tients with M/S PAR.
Variable Control M PAR M/S PAR
IL-17A gene expression 0.1267 ± 0.89 0.6103 ± 0.15ab 1.0570 ± 0.42bc
IL-22 gene expression 0.2525 ± 0.19 0.7277 ± 0.18ab 1.1527 ± 0.39bc
Serum IL-17A level 4.88 ± 2.34 18.55 ± 3.60ab 61.55 ± 18.49bc
Serum IL-22 level 14.55 ± 7.63 42.36 ± 11.86ab 80.81 ± 23.10bc
IL-17A positive cells per
ﬁeld
57.57 ± 5.41 62.70 ± 10.82 65.73 ± 6.79bc
IL-22 positive cells per
ﬁeld
68.30 ± 7.24 76.43 ± 12.64ab 83.07 ± 8.34bc
Results are shown as mean ± SD. A: a statistically signiﬁcant diﬀerence be-
tween patients with mild persistent allergic rhinitis (M PAR) and healthy con-
trols, B: a statistically signiﬁcant diﬀerence between patients with mild per-
sistent allergic rhinitis (M PAR) and patients with moderate/severe persistent
allergic rhinitis (M/S PAR), and C: a statistically signiﬁcant diﬀerence between
healthy controls and patients with M/S PAR.
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3.6. Serum levels of IL-17A and IL-22 in healthy controls, patients with M/
S PAR, and patients with M PAR
IL-17A and IL-22 levels (pg/ml) were measured in serum of the
patients with M/S PAR, patients with M PAR, and healthy controls
(Fig. 4A, B). In comparison with healthy participants (P < 0.05) and
patients with M PAR, signiﬁcantly higher levels of IL-17A and IL-22
were found in serum of patients with M/S PAR. Likewise, the diﬀer-
ences between the serum levels of IL-17A and IL-22 in M PAR patients
and healthy controls were statistically signiﬁcant (P < 0.05) (Fig. 4)
(Table 3).
3.7. Associations between the serum levels of IL-17A and the clinical
characteristics and disease severity of patients with M/S PAR
There were signiﬁcant correlations between serum levels of IL-17A
and TNSS (R=0.654; P < 0.05; data not shown), tIgE (R=0.575;
P < 0.05; data not shown), sIgE (R= 0.561; P < 0.05; data not
shown), blood eosinophil counts (R= 0.393; P < 0.05; data not
shown), and degree of eosinophil inﬁltration into nasal (R=0.405;
P < 0.05; data not shown).
3.8. Associations between the serum levels of IL-22 and the clinical
characteristics and disease severity of patients with M/S PAR
Signiﬁcant correlations were observed between serum levels of IL-
22 and TNSS (R= 0.716; P < 0.05; data not shown), tIgE (R= 0.342;
P < 0.05; data not shown), sIgE (R= 0.568; P < 0.05; data not
shown), and the degree of eosinophil inﬁltration into the nasal mucosa
(R=0.556; P < 0.05; data not shown). However, the correlation be-
tween the serum levels of IL-22 and blood eosinophil counts
(R=0.261; P > 0.05; data not shown) was not statistically signiﬁcant.
4. Discussion
In the present well-characterized cohort study, the exact cellular
localization and expression patterns of IL-17A and IL-22 in human nasal
mucosa of the inferior turbinate as well as the serum levels were de-
scribed. Associations among expression of IL-17A, expression of IL-22,
and immunopathogensis of M/S PAR including disease severity and
clinical characteristics, were also speciﬁed. To the best of researchers'
knowledge, this study is the ﬁrst one demonstrating the local produc-
tion of IL-22 in nasal mucosa. The ﬁndings of the present study revealed
that there were observable increases in the serum levels, gene expres-
sion, and local production of IL-22 in patients with M/S PAR compared
with patients with M PAR and healthy controls. In line with the men-
tioned ﬁnding, in comparison with healthy individuals, serum levels of
IL-22 have been observed to be up-regulated in patients with AR [19].
Likewise, serum levels and gene expression of IL-17A increased in pa-
tients with M/S PAR compared with M PAR and control groups. These
results are in accordance with those obtained from other studies re-
vealing the increased serum levels of IL-17A in patients with AR in
comparison with healthy controls [8,20]. In contrast, the ﬁndings of
another study indicated that the diﬀerence of serum levels of IL-17A
between patients with AR and healthy controls was not statistically
signiﬁcant [21]. Interestingly, there were not any considerable diﬀer-
ences in the local production of IL-17A in patients with M/S PAR and M
PAR; in contrast, local production of IL-17A was signiﬁcantly higher in
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patients with M/S PAR in comparison with control group. The results of
this study indicated that IL-17A+ cells, IL-22+ cells, and serum levels of
IL-17A and IL-22 were highly and positively correlated with sIgE and
the number of eosinophil inﬁltration into nasal mucosa. These results
are conﬁrmed by previous studies indicating the correlations among
serum levels of IL-17A and the number of eosinophil inﬁltration into
nasal mucosa [22] and sIgE [5,20]. Moreover, the association between
serum levels of IL-22 and sIgE [19] indicated in the already conducted
studies is in line with the ﬁndings of the present study. A limited
chronic inﬂammation and the priming eﬀect are stimulated by eosi-
nophil inﬁltration into the nasal mucosa, both of which can intensify
nasal hyperactivity [23]. Therefore, IL-17A and IL-22 may induce in-
ﬂammation via enrichment of eosinophilic swelling. The present study
demonstrated that serum levels of IL-22 did not associate with tIgE and
blood eosinophil count; however, serum levels of IL-17A and IL-
22+cells were positively correlated with tIgE and blood eosinophil
count. The ﬁndings of this study indicated that IL-17A+ cells associated
with tIgE, although they indicated no correlations with blood eosino-
phil count. Makihara et al. [24] reported that IL-17A+ did not correlate
with tIgE and blood eosinophil count. Similar to results of this study,
Ciprandi et al.'s [8] study indicated that serum levels of IL-17A corre-
lated with blood eosinophil count. Moreover, Farfariello et al. [25]
reported that serum levels of IL-22 did not correlate with tIgE. In this
regard, more controversial results are presented addressing the corre-
lations between IL-17A and TNSS. Ciprandi et al. [8] stated that serum
levels of IL-17A were associated with TNSS in patients with AR, which
was conﬁrmed by the results of Nieminen et al.'s study [6]. Conversely,
Lie et al. [26] and Klemenes et al. [27] reported that there were not any
correlations between TNSS and serum levels of IL-17A in patients with
AR. The current study showed that serum levels and local production of
IL-22 and IL-17A statistically correlated with TNSS. The mentioned
ﬁnding suggests that IL-17A and IL-22 are closely associated with the
disease severity of M/S PAR.
In conclusion, this study provides the ﬁrst report regarding the local
production of IL-22 in inferior turbinate of nasal mucosa of patients
suﬀering from PAR. Furthermore, the correlations between IL-22 and
disease parameters are presented. Hence, these results strengthen the
claim that IL-17A and IL-22 could be considered as potential markers of
PAR severity.
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